Cutaneous sarcoidosis: six trials, 156 patients, and nothing beats placebo

Design

systematic review and random-effects meta-analysis of randomised placebo-controlled trials, PubMed, Cochrane and ClinicalTrials.gov searched to January 2025

Population

six randomised trials, 156 adults with cutaneous sarcoidosis

Primary outcome

clinical response, quality of life and serious adverse events versus placebo

Effect

clinical response OR 2.24 (95% CI 0.73-6.90, p = 0.16); quality of life OR 2.23 (0.87-5.73, p = 0.09); serious adverse events OR 0.97 (0.48-1.96)

Cutaneous sarcoidosis is disfiguring, has a substantial quality-of-life burden, and is treated with a long list of systemic and targeted agents chosen largely by habit. This meta-analysis asked what the randomised placebo-controlled evidence actually shows, searching to January 2025 and finding six trials with 156 participants between them.

Pharmacological add-on therapy did not significantly improve clinical response over placebo (OR 2.24, 95% CI 0.73 to 6.90, p = 0.16). Quality of life showed a trend that did not reach significance (OR 2.23, 95% CI 0.87 to 5.73, p = 0.09). Serious adverse events did not differ between groups (OR 0.97, 95% CI 0.48 to 1.96). Risk of bias was moderate to high, though statistical heterogeneity was low.

This is an absence of evidence, not evidence of absence, and the distinction matters for how you use it. Six trials totalling 156 patients cannot exclude a clinically worthwhile effect — the point estimate of 2.24 is in the direction of benefit and the interval simply cannot rule out chance. What the analysis does establish is that the confident tone with which these agents are recommended is not earned. The practical consequence is in the consultation: a patient started on an add-on systemic for cutaneous sarcoidosis should be told the evidence base is six small trials, and the treatment should have a defined review point at which it is stopped if it is not working.

• Tell patients the evidence base for add-on systemic therapy in cutaneous sarcoidosis is six small trials
• Set an explicit response assessment date at the point of starting, and stop if the response is not there
• Do not read a non-significant pooled result as proof the drugs do not work — the trials are too small to say
• Quality of life is a legitimate treatment goal here and showed the more promising trend
• Weigh the toxicity of each agent individually; the pooled serious adverse event finding does not exonerate any specific drug

The statistics, in plain English

An odds ratio of 2.24 with an interval running from 0.73 to 6.90 crosses 1.0, so the result is inconclusive rather than negative — the data are compatible with substantial benefit and with mild harm. That width comes almost entirely from having only 156 patients across six trials. Low statistical heterogeneity means the trials agreed with each other, which is reassuring about consistency but does not compensate for moderate-to-high risk of bias in the trials themselves.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.